Liarozole

Drugs and Aging

Volumn 9, Issue 6, 1996, Pages 478-484

  Bryson, H M ^a   Wagstaff, A J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; AROMATASE; ESTROGEN; LIAROZOLE; OXYGENASE; RETINOIC ACID; STEROID 17,20 LYASE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CATABOLISM; CHEMOPROPHYLAXIS; CLINICAL TRIAL; ENZYME INHIBITION; FEEDBACK SYSTEM; HORMONE INHIBITION; HUMAN; HYPOPHYSIS; META ANALYSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PSORIASIS; PUBLICATION; RELAPSE; REVIEW; SKIN MANIFESTATION; TESTIS; TESTOSTERONE BLOOD LEVEL;

EID: 0030450453     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609060-00010     Document Type: Review

References (29)

1. 1. H Vanden Bossche 1992 Inhibitors of P450-dependent steroid biosynthesis: from research to medical treatment J Steroid Biochem Mol Biol 43 8 1003 21 22217845 10.1016/0960-0760(92)90328-G 1:CAS:528:DyaK3sXktF2kt7s%3D Vanden Bossche H. Inhibitors of P450-dependent steroid biosynthesis: from research to medical treatment. J Steroid Biochem Mol Biol 1992; 43(8): 1003–21
2. 2. W Kreis 1995 Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer Cancer Invest 13 296 312 7743383 10.3109/07357909509094465 1:STN:280:DyaK2M3mtF2kuw%3D%3D Kreis W. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 1995 May; 13: 296–312
3. 3. DP Dearnaley A Price RJ Shearer 1993 Prostate cancer Lancet 342 901 5 10.1016/0140-6736(93)91949-M Dearnaley DP, Price A, Shearer RJ, et al. Prostate cancer. Lancet 1993 Oct 9; 342: 901–5
4. 4. C Mahler LJ Denis 1995 Hormone refractory disease Semin Surg Oncol 11 77 83 7538695 10.1002/ssu.2980110112 1:STN:280:DyaK2M3ntlyltA%3D%3D Mahler C, Denis LJ. Hormone refractory disease. Semin Surg Oncol 1995 Jan–Feb; 11: 77–83
5. 5. WK Kelly HI Scher 1994 Prostate cancer: How can a common disease be so controversial? Curr Opin Oncol 6 3 318 31 8080862 10.1097/00001622-199405000-00016 1:STN:280:DyaK2czmt1Srsg%3D%3D Kelly WK, Scher HI. Prostate cancer: How can a common disease be so controversial? Curr Opin Oncol 1994; 6(3): 318–31
6. 6. J Wauwe Van G Nyen Van MC Coene 1992 Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo J Pharmacol Exp Ther 261 773 9 1374473 Van Wauwe J, Van Nyen G, Coene MC, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992 May; 261: 773–9
7. 7. MDWG Krekels J Zimmerman B Janssens 1996 Analysis of the oxidative catabolism of retinoic acid in rat Dunning R3327G prostate tumours Prostate 29 36 41 8685053 10.1002/(SICI)1097-0045(199607)29:1<36::AID-PROS5>3.0.CO;2-G 1:CAS:528:DyaK28XltVags7c%3D Krekels MDWG, Zimmerman J, Janssens B, et al. Analysis of the oxidative catabolism of retinoic acid in rat Dunning R3327G prostate tumours. Prostate 1996 Jul; 29: 36–41
8. 8. W Wouters J Dun van A Dillen 1992 Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells Cancer Res 52 2841 6 1581897 1:CAS:528:DyaK38XktVSntLo%3D Wouters W, van Dun J, Dillen A, et al. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 1992 May 15; 52: 2841–6
9. 9. R Coster De W Wouters R Ginckel Van 1992 Experimental studies with liarozole (R 75251): an antitumoral agent which inhibits retinoic acid breakdown J Steroid Biochem Mol Biol 43 197 201 1525060 10.1016/0960-0760(92)90208-Z De Coster R, Wouters W, Van Ginckel R, et al. Experimental studies with liarozole (R 75251): an antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol 1992 Sep; 43: 197–201
10. 10. P Acevedo JS Bertram 1995 Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and β-carotene in 10T1/2 cells Carcinogenesis 16 2215 22 7554078 10.1093/carcin/16.9.2215 1:CAS:528:DyaK2MXot1ansLs%3D Acevedo P, Bertram JS. Liarozole potentiates the cancer chemopreventive activity of and the up-regulation of gap junctional communication and connexin43 expression by retinoic acid and β-carotene in 10T1/2 cells. Carcinogenesis 1995 Sep; 16: 2215–22
11. 11. JP Wauwe Van MC Coene J Goossens 1990 Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats J Pharmacol Exp Ther 252 365 9 2299598 Van Wauwe JP, Coene MC, Goossens J, et al. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 1990 Jan; 252: 365–9
12. 12. CC Achkar JM Bentel JF Boylan 1994 Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice Drug Metab Dispos 22 451 8 8070324 1:CAS:528:DyaK2cXktVShsrc%3D Achkar CC, Bentel JM, Boylan JF, et al. Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. Drug Metab Dispos 1994 May–Jun; 22: 451–8
13. 13. VA Miller JR Rigas JRF Muindi 1994 Modulation of all-trans retinoic acid pharmacokinetics by liarozole Cancer Chemother Pharmacol 34 522 6 7923564 10.1007/BF00685665 1:CAS:528:DyaK2MXis1Omsr0%3D Miller VA, Rigas JR, Muindi JRF, et al. Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol 1994 Sep; 34: 522–6
14. 14. J Bruynseels R Coster De P Rooy Van 1990 R 75251, a new inhibitor of steroid biosynthesis Prostate 16 345 57 2164659 10.1002/pros.2990160409 1:CAS:528:DyaK3cXmtVCnu7c%3D Bruynseels J, De Coster R, Van Rooy P, et al. R 75251, a new inhibitor of steroid biosynthesis. Prostate 1990; 16: 345–57
15. 15. R Coster De W Wouters J Bruynseels 1996 P 450-dependent enzymes as targets for prostate cancer therapy J Steroid Biochem Mol Biol 56 1–6 133 43 8603034 10.1016/0960-0760(95)00230-8 De Coster R, Wouters W, Bruynseels J. P 450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 1996; 56(1–6): 133–43
16. 16. GA Dijkman RJA Moorselaar Van R Ginckel Van 1994 Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas J Urol 151 217 22 8254818 1:STN:280:DyaK2c%2Fns1GjtA%3D%3D Dijkman GA, Van Moorselaar RJA, Van Ginckel R, et al. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas. J Urol 1994 Jan; 151: 217–22
17. 17. R Ginckel Van R Coster De W Wouters 1990 Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats Prostate 16 313 23 2371176 10.1002/pros.2990160406 Van Ginckel R, De Coster R, Wouters W, et al. Antitumoral effects of R 75251 on the growth of transplantable R3327 prostatic adenocarcinoma in rats. Prostate 1990; 16: 313–23
18. 18. G Smets R Ginckel Van G Daneels 1995 Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid Prostate 27 129 40 7567691 10.1002/pros.2990270303 1:CAS:528:DyaK2MXptFSitb8%3D Smets G, Van Ginckel R, Daneels G, et al. Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. Prostate 1995 Sep; 27: 129–40
19. 19. ME Stearns M Wang K Fudge 1993 Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity Cancer Res 53 3073 7 8319215 1:CAS:528:DyaK3sXlsFWkur0%3D Stearns ME, Wang M, Fudge K. Liarozole and 13-cis-retinoic acid anti-prostatic tumor activity. Cancer Res 1993 Jul 1; 53: 3073–7
20. 20. KVN Rao DL McCormick MC Bosland 1996 Chemopreventive efficacy evaluation of liarozole fumarate, difluoromethylornithine, and oltipraz in the rat prostate Proceedings of the American Association for Cancer Research 37 273 [abstract no. 1864] Rao KVN, McCormick DL, Bosland MC, et al. Chemopreventive efficacy evaluation of liarozole fumarate, difluoromethylornithine, and oltipraz in the rat prostate[abstract no. 1864]. Proceedings of the American Association for Cancer Research; 1996 Mar; 37: 273
21. 21. MW Horton JA Barone JJ Raia 1991 Effect of food and gastric acidity on the bioavailability of orally administered R75,251 Pharmacotherapy 11 3 275 [abstract no. 76] Horton MW, Barone JA, Raia JJ, et al. Effect of food and gastric acidity on the bioavailability of orally administered R75,251[abstract no. 76]. Pharmacotherapy 1991; 11(3): 275
22. 22. L Denis 1995 Liarozole-fumarate (LIA), a novel antitumoral drug: clinical update International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer [poster] Denis L. Liarozole-fumarate (LIA), a novel antitumoral drug: clinical update [poster]. International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer; 1995 Sep 21–23; Quebec, Canada
23. 23. EJ Seidmon DL Trump W Kreis 1995 Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate Ann Surg Oncol 2 550 6 8591087 10.1007/BF02307090 1:STN:280:DyaK287is1CjsA%3D%3D Seidmon EJ, Trump DL, Kreis W, et al. Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate. Ann Surg Oncol 1995 Nov; 2: 550–6
24. 24. F Boccardo D Cannata D Guarneri 1994 R75251 in prostate cancer patients in progression after first-line hormonal treatment Tumori 80 276 9 7526509 1:STN:280:DyaK2M%2FmsFWltw%3D%3D Boccardo F, Cannata D, Guarneri D, et al. R75251 in prostate cancer patients in progression after first-line hormonal treatment. Tumori 1994 Aug 31; 80: 276–9
25. 25. Data on file (LIA-CAN-1/2), Janssen Pharmaceutica
26. 26. Denis L. Liarozole fumarate (LIA), a novel antitumoral drug: clinical update[abstract no. 21]. Proceedings of the International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer; 1995 Sep 21–23; Quebec, Canada: 16
27. 27. Denis L, Debruyne FMJ, Mahler C, et al. Liarozole-HCl (R75251), a novel treatment in hormone-resistant prostatic cancer: response to PSA [abstract no. 28]. 11th Cong Eur Assoc Urol; 1994 Jul 13–16; Berlin, Germany: 14
28. 28. J Smith G Andriole F Ahmann 1996 Effects of liarozole (LIA) on PSA levels in patients with relapsed stage D prostate cancer Proc Am Soc Clin Oncol 15 250 [abstract no. 636] Smith J, Andriole G, Ahmann F, et al. Effects of liarozole (LIA) on PSA levels in patients with relapsed stage D prostate cancer [abstract no. 636]. Proc Am Soc Clin Oncol 1996 Mar; 15: 250
29. 29. C Mahler L Denis R Coster De 1989 The effects of a new imidazole derivative in advanced prostatic cancer: a preliminary report Prog Clin Biol Res 303 205 9 2476819 1:STN:280:DyaL1Mzos1ykug%3D%3D Mahler C, Denis L, De Coster R. The effects of a new imidazole derivative in advanced prostatic cancer: a preliminary report. Prog Clin Biol Res 1989; 303: 205–9